EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PKM splice-switching ASOs induce upregulation of dual-specificity phosphatases and dephosphorylation of ERK1/2 in hepatocellular carcinoma

Dillon M Voss, Alexander J Kral, GeunYoung Sim, Raditya Utama, Kuan-Ting Lin, Chris Cizmeciyan, Balazs Schafer, Patrick J Cunniff, Christopher R Vakoc, Marvin H Caruthers, Lopa Mishra, Adrian R Krainer

Journal of Biological Chemistry · 2025

DOI: 10.1016/j.jbc.2025.108345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Dillon M Voss und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cold Spring Harbor Laboratory, New York, USA; Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Membrane Proteins, Alternative Splicing. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAAA NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyruvate kinase muscle isoform 2 (PKM2) is preferentially expressed in nearly all cancers. It primarily functions as the last enzyme in glycolysis but has other reported noncanonical functions, including recruiting transcription factors to oncogenes and phosphorylating proteins. We previously described antisense oligonucleotides that disrupt alternative splicing of PKM pre-mRNA (PKM-ASOs), resulting in a PKM2-to-PKM1 isoform switch in hepatocellular carcinoma (HCC), which reduces HCC growth in vitro and in vivo. PKM1 has higher enzymatic activity than PKM2, which potentially drives metabolism away from macromolecule synthesis, and may explain decreased HCC growth upon PKM-ASO treatment. As PKM-ASOs also reduce PKM2 levels, how PKM splice-switching inhibits HCC cell proliferation was unclear. Here, we characterized the individual consequences of altering PKM1 or PKM2 protein levels in HCC and observed that reducing PKM2 alone was sufficient to decrease HCC cell proliferation, whereas overexpressing PKM1 had no effect. Moreover, increasing PK activity via a small-molecule PKM2 activator had no effect on HCC cell proliferation, suggesting that PKM-ASOs affect PKM2's nonmetabolic functions. Transcriptomic and RT-qPCR analyses of HCC cells treated with PKM-ASO or PKM2-siRNA revealed upregulation of dual-specificity phosphatase 2 (DUSP2) and other related DUSPs, which act directly on ERK1/2 in the MAPK signaling pathway. Luciferase reporter assays demonstrated that PKM-ASO treatment activated the DUSP2 promoter, which correlated with decreased ERK1/2 phosphorylation. Lenvatinib is a second-line HCC therapy that indirectly reduces ERK1/2 phosphorylation, and combined treatment with PKM-ASOs inhibited proliferation of HCC cells more than either treatment alone. In summary, our results reveal a mechanism by which PKM-ASOs affect PKM2 dependency in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMembrane ProteinsAlternative SplicingOligonucleotides, AntisenseMitogen-Activated Protein Kinase 3Thyroid HormonesMitogen-Activated Protein Kinase 1Pyruvate KinaseMAP Kinase Signaling SystemHumansCell ProliferationPhosphorylationUp-RegulationThyroid Hormone-Binding ProteinsCell Line, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

antisense RNAcancerdual-specificity phosphoprotein phosphatasehepatocellular carcinomapyruvate kinase

Substanzen

Membrane ProteinsOligonucleotides, AntisenseThyroid Hormone-Binding ProteinsMitogen-Activated Protein Kinase 3Thyroid HormonesMitogen-Activated Protein Kinase 1Pyruvate KinaseMAPK3 protein, humanMAPK1 protein, human

Autor:innen und Institutionen

  • Cold Spring Harbor Laboratory, New York, USA; Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
  • Cold Spring Harbor Laboratory, New York, USA; Department of Microbiology and Immunology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
  • Cold Spring Harbor Laboratory, New York, USA.
  • Department of Biochemistry, University of Colorado, Boulder, Colorado, USA.
  • Cold Spring Harbor Laboratory, New York, USA; The Institute for Bioelectronic Medicine, The Feinstein Institutes for Medical Research, Division of Gastroenterology and Hepatology, Northwell Health, New York, USA.
  • Cold Spring Harbor Laboratory, New York, USA. Electronic address: Krainer@cshl.edu.

Förderung

  • NCI NIH HHS
  • NIAAA NIH HHS
  • NIGMS NIH HHS
  • Cold Spring Harbor Laboratory
  • NIH National Institute of General Medical Sciences
  • National Institutes of Health
  • University of Colorado Boulder
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Voss, D. M., Kral, A. J., Sim, G., Utama, R., Lin, K. T., Cizmeciyan, C., Schafer, B., Cunniff, P. J., Vakoc, C. R., Caruthers, M. H., Mishra, L., & Krainer, A. R. (2025). PKM splice-switching ASOs induce upregulation of dual-specificity phosphatases and dephosphorylation of ERK1/2 in hepatocellular carcinoma. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108345

Vancouver

Voss DM, Kral AJ, Sim G, Utama R, Lin KT, Cizmeciyan C, et al. PKM splice-switching ASOs induce upregulation of dual-specificity phosphatases and dephosphorylation of ERK1/2 in hepatocellular carcinoma. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108345

BibTeX
@article{Voss2025,
  author = {Voss, Dillon M and Kral, Alexander J and Sim, GeunYoung and Utama, Raditya and Lin, Kuan-Ting and Cizmeciyan, Chris and Schafer, Balazs and Cunniff, Patrick J and Vakoc, Christopher R and Caruthers, Marvin H and Mishra, Lopa and Krainer, Adrian R},
  title = {PKM splice-switching ASOs induce upregulation of dual-specificity phosphatases and dephosphorylation of ERK1/2 in hepatocellular carcinoma},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.108345}
}
Kostenlos starten →